SI1501819T1 - Modulatorji estrogen receptorjev - Google Patents

Modulatorji estrogen receptorjev

Info

Publication number
SI1501819T1
SI1501819T1 SI200331909T SI200331909T SI1501819T1 SI 1501819 T1 SI1501819 T1 SI 1501819T1 SI 200331909 T SI200331909 T SI 200331909T SI 200331909 T SI200331909 T SI 200331909T SI 1501819 T1 SI1501819 T1 SI 1501819T1
Authority
SI
Slovenia
Prior art keywords
estrogen
receptor modulators
compounds
estrogen receptor
functioning
Prior art date
Application number
SI200331909T
Other languages
English (en)
Inventor
Frank P Dininno
Timothy Allen Blizzard
Jerry Dwain Ii Morgan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SI1501819T1 publication Critical patent/SI1501819T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SI200331909T 2002-04-24 2003-04-18 Modulatorji estrogen receptorjev SI1501819T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37523702P 2002-04-24 2002-04-24
PCT/US2003/012103 WO2003091239A1 (en) 2002-04-24 2003-04-18 Estrogen receptor modulators
EP03736470A EP1501819B1 (en) 2002-04-24 2003-04-18 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
SI1501819T1 true SI1501819T1 (sl) 2011-01-31

Family

ID=29270611

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331909T SI1501819T1 (sl) 2002-04-24 2003-04-18 Modulatorji estrogen receptorjev

Country Status (13)

Country Link
US (1) US7138426B2 (sl)
EP (1) EP1501819B1 (sl)
JP (1) JP4554219B2 (sl)
AT (1) ATE481397T1 (sl)
AU (1) AU2003237084C1 (sl)
CA (1) CA2484038C (sl)
CY (1) CY1111195T1 (sl)
DE (1) DE60334202D1 (sl)
DK (1) DK1501819T3 (sl)
ES (1) ES2350446T3 (sl)
PT (1) PT1501819E (sl)
SI (1) SI1501819T1 (sl)
WO (1) WO2003091239A1 (sl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588180A1 (en) * 2004-12-17 2006-06-22 Bionovo, Inc. Method of using extracts of epimedium species
EP1944301A4 (en) * 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
CN101389623A (zh) * 2006-02-28 2009-03-18 阿斯利康(瑞典)有限公司 吲哚衍生物的新的盐及其在医药中的用途
WO2008002490A2 (en) * 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20080119444A1 (en) * 2006-11-16 2008-05-22 Steven Lehrer Methods and compositions for the treatment of cancer
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
MX2010006972A (es) 2007-12-21 2010-08-26 Ligand Pharm Inc Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
DK2580210T5 (en) * 2010-06-10 2017-06-19 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
AU2011347718B2 (en) 2010-12-24 2016-06-23 Msd Oss B.V. N-substituted azetidine derivatives
JP6112625B2 (ja) 2011-12-14 2017-04-12 セラゴン ファーマシューティカルズ，インク． フッ素化したエストロゲン受容体モジュレーターおよびその使用
WO2013090921A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
WO2013130832A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
UY37124A (es) 2016-02-15 2017-09-29 Sanofi Sa Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CA3027563A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2018091153A1 (en) * 2016-11-17 2018-05-24 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP4374925A2 (en) 2017-01-05 2024-05-29 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
BR112020014746A2 (pt) * 2018-01-22 2020-12-08 Radius Pharmaceuticals, Inc. Compostos moduladores de receptor de estrogênio
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
MX2021002666A (es) 2018-09-07 2021-07-16 Sanofi Sa Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ268198A3 (cs) 1996-02-24 1999-02-17 Basf Aktiengesellschaft 2-hetaroylcyklohexan- 1,3-diony, způsob jejich výroby a jejich použití
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
FR2762598A1 (fr) 1997-04-25 1998-10-30 Adir Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennnent
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
JP2004511501A (ja) 2000-10-19 2004-04-15 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体モジュレーター
US6750213B2 (en) * 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
JP2004511502A (ja) * 2000-10-19 2004-04-15 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体モジュレーター
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators

Also Published As

Publication number Publication date
EP1501819A4 (en) 2006-06-21
WO2003091239A1 (en) 2003-11-06
JP4554219B2 (ja) 2010-09-29
CA2484038A1 (en) 2003-11-06
AU2003237084C1 (en) 2009-03-26
PT1501819E (pt) 2010-11-11
AU2003237084B2 (en) 2008-11-20
US7138426B2 (en) 2006-11-21
AU2003237084A1 (en) 2003-11-10
JP2005529136A (ja) 2005-09-29
ES2350446T3 (es) 2011-01-24
US20050234245A1 (en) 2005-10-20
EP1501819A1 (en) 2005-02-02
DK1501819T3 (da) 2011-01-10
DE60334202D1 (de) 2010-10-28
CY1111195T1 (el) 2015-06-11
CA2484038C (en) 2011-10-18
EP1501819B1 (en) 2010-09-15
ATE481397T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
EP1501819A4 (en) MODULATORS OF THE ESTROGEN RECEPTOR
EP1257264A4 (en) ESTROGEN RECEPTOR MODULATORS
WO2002091993A3 (en) Estrogen receptor modulators
TW200631933A (en) Estrogen receptor modulators
MX2007006878A (es) Moduladores del receptor de estrogeno.
AU2696502A (en) Estrogen receptor modulators
WO2002032377A3 (en) Estrogen receptor modulators
WO2004073612A3 (en) Estrogen receptor modulators
WO2006081152A3 (en) Estrogen receptor modulators
WO2004091488A3 (en) Estrogen receptor modulators
WO2003016270A3 (en) Selective estrogen receptor modulators
WO2002032373A3 (en) Estrogen receptor modulators
EP1943224A4 (en) Estrogen receptor modulators
AU2003288644A1 (en) Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof
WO2005097141A3 (en) Estrogen receptor modulators
WO2004073610A3 (en) Estrogen receptor modulators
WO2002053522A3 (en) Novel estrogen receptor ligands and methods i
WO2002058639A3 (en) Pyranoflavonoid compounds and their use as estrogen receptor modulators
AR039282A1 (es) Moduladores de receptores de estrogeno
WO2004026887A3 (en) Estrogen receptor modulators
WO2008057309A3 (en) Estrogen receptor modulators
WO2009059806A3 (en) Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine
DOP2002000384A (es) Moduladores de receptores estrogenicos.
DOP2005000224A (es) Moduladores de los receptores de estrogeno